Workflow
天津发展(00882.HK)附属力生制药出资1.74亿元参设5亿元医疗健康基金
Ge Long Hui·2025-08-21 22:48

Group 1 - The company Tianjin Development (00882.HK) announced its indirect subsidiary, Lisheng Pharmaceutical (002393.SZ), plans to establish a fund with a total proposed subscription amount of RMB 500 million, with Lisheng contributing RMB 173.75 million, accounting for 34.75% of the total [1] - The fund, tentatively named Jian Sheng Guo Xin Tai Da Equity Fund Partnership (Limited Partnership), has a proposed duration of five years and will primarily invest in the health and biotechnology sectors in China [1] - The establishment of this fund is expected to deepen the company's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [2] Group 2 - The company believes that investing in the fund will provide more industry acquisition opportunities aligned with its development strategy and offer potential returns beyond fixed income, thereby improving capital allocation efficiency and enhancing capital returns [2]